Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:9 Issue:11 Number:21 ISSN#:2563-5476
ACE Report #12587
Ace Report Cover General Orthopaedics

Effect of Bamlanivimab (LY-CoV555) Antibody Treatment on Viral Load & Clinical Outcomes for COVID-19

How to Cite

OrthoEvidence. Effect of Bamlanivimab (LY-CoV555) Antibody Treatment on Viral Load & Clinical Outcomes for COVID-19. ACE Report. 2020;9(11):21. Available from: https://myorthoevidene.com/AceReport/Report/12587

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

N Engl J Med. 2020 Oct 28.

Contributing Authors: P Chen A Nirula J Morris B Heller RL Gottlieb J Boscia G Huhn B Mocherla V Stosor AC Adams J Van Naarden KL Custer L Shen M Durante G Oakley AE Schade J Sabo DR Patel P Klekotka DM Skovronsky BLAZE-1 Investigators

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


Four hundred and fifty two patients who tested positive for coronavirus disease 19 (COVID19) were randomized to receive a single intravenous infusion of LY-CoV555, at a dose of 700mg, 2800mg, or 7000mg, or placebo, for the reduction of viral load and amelioration of symptoms. The primary outcome of interest was the change from baseline in viral load at 11 days follow up. Secondary outcomes of inte...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.